---
title: "BHVN.US (BHVN.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BHVN.US/news.md"
symbol: "BHVN.US"
name: "BHVN.US"
parent: "https://longbridge.com/en/quote/BHVN.US.md"
datetime: "2026-03-14T05:05:25.050Z"
locales:
  - [en](https://longbridge.com/en/quote/BHVN.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BHVN.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BHVN.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/BHVN.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/BHVN.US/news.md)


# BHVN.US (BHVN.US) — Related News

### [What's Going On With Biohaven Stock On Monday?](https://longbridge.com/en/news/278419943.md)
*2026-03-09T15:47:31.000Z*
> Biohaven Ltd (NYSE:BHVN) shares rose in premarket trading to $12.52 following positive results from Xenon Pharmaceutical

### [Key facts: Biohaven posts $738.8M loss; opakalim shows promise in study; analysts give 'buy' rating](https://longbridge.com/en/news/277672280.md)
*2026-03-03T20:04:13.000Z*
> Biohaven Ltd. posted a net loss of $738.8 million for 2025, an improvement from last year, with no product revenue and a

### [16:05 ETBiohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results](https://longbridge.com/en/news/277517827.md)
*2026-03-02T21:05:36.000Z*
> Biohaven Ltd. reported its fourth quarter and full year 2025 financial results, highlighting advancements in key clinica

### [Biohaven Ltd. (BHVN): A bull case theory](https://longbridge.com/en/news/277314305.md)
*2026-02-28T15:21:16.000Z*
> A bullish thesis on Biohaven Ltd. (BHVN) was presented by Danny Green on his Substack. The article highlights the potent

### [Assessing Biohaven (BHVN) Valuation After A Sharp One Year Decline And Recent Three Month Rebound](https://longbridge.com/en/news/276854341.md)
*2026-02-25T08:16:13.000Z*
> Biohaven (BHVN) has experienced a mixed performance, with a recent 25.1% gain over three months contrasting a 67.4% decl

### [Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA | HNSA Stock News](https://longbridge.com/en/news/276264453.md)
*2026-02-18T11:28:00.000Z*
> Hansa Biopharma AB announced that the FDA has accepted its Biologics License Application (BLA) for imlifidase. The revie

### [Hansa Biopharma Earnings Call Marks Pivotal 2026 Pivot](https://longbridge.com/en/news/275675722.md)
*2026-02-12T00:02:44.000Z*
> Hansa Biopharma's Q4 earnings call highlighted strong revenue growth, with total revenue up 135% year-on-year to SEK 76.

### [04:09 ETHanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026](https://longbridge.com/en/news/274944807.md)
*2026-02-05T09:10:36.000Z*
> HanchorBio, Inc. (TPEx: 7827) announced a series of scientific presentations at major oncology congresses in Q1 2026, sh

### [Sector Update: Health Care Stocks Rise in Afternoon Trading](https://longbridge.com/en/news/273270891.md)
*2026-01-21T18:40:00.000Z*
> Health care stocks experienced a rise in afternoon trading, with the NYSE Health Care Index up 1%. Dr. Reddy's Laborator

### [](https://longbridge.com/en/news/273245182.md)
*2026-01-21T14:21:37.000Z*
> Biohaven shares are trading higher after RBC Capital upgraded the stock from Sector Perform to Outperform and raised its